Chikungunya Market Report 2026

Chikungunya Market Overview

• Chikungunya market size has reached to $0.65 billion in 2025 • Expected to grow to $1 billion in 2030 at a compound annual growth rate (CAGR) of 9.1% • Growth Driver: Increasing Global Incidence Of Mosquito-Borne Diseases Driving Market Growth • Market Trend: Innovative Chikungunya Vaccines Advancing Immunity And Disease Prevention • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chikungunya Market?

Chikungunya (CHIKV) is a viral infection caused by the chikungunya virus, primarily transmitted to humans through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes. The virus causes fever, joint pain, headache, rash, and muscle pain, significantly impacting the quality of life of affected individuals. The main product types for chikungunya include antiviral drugs, herbal and complementary treatments, supportive care, and vaccines. Antiviral drugs are medications designed to prevent or treat viral infections by inhibiting the replication of viruses in the body. These products are available in various forms, such as liquid, powder, and solid forms. These are applied at different stages of the disease, including acute, chronic, and post-infection stages. These are distributed through multiple sales channels, including hospital pharmacies, online pharmacies, retail pharmacies, and supermarkets and are used by various end users such as caregivers, healthcare professionals, and patients.

What Is The Chikungunya Market Growth Forecast?

The chikungunya market size is expected to see strong growth in the next few years. It will grow to $1 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to increasing investments in vaccine research, rising focus on preventive healthcare, expansion of vector control programs, growing demand for rapid diagnostic solutions, increased global health funding for emerging diseases. Major trends in the forecast period include increasing development of chikungunya vaccines, rising adoption of antiviral treatment protocols, growing focus on early disease diagnosis, expansion of supportive care solutions, enhanced surveillance of mosquito-borne diseases.

Global Chikungunya Market Segmentation

1) By Type: Antiviral Drugs, Herbal And Complementary Treatments, Supportive Care, Vaccines 2) By Product Form: Liquid Form, Powder, Solid Form 3) By Disease Stage: Acute, Chronic, Post-Infection 4) By Sales Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Supermarkets 5) By End User: Caregivers, Healthcare Professionals, Patients Subsegments: 1) By Antiviral Drugs: Nucleoside Analogues, Protease Inhibitors 2) By Herbal And Complementary Treatments: Ayurvedic Remedies, Homeopathic Treatments, Traditional Chinese Medicine 3) By Supportive Care: Pain Relievers (NSAIDs, Acetaminophen), Fluid Therapy, Physiotherapy 4) By Vaccines: Live-Attenuated Vaccines, Inactivated Vaccines, mRNA-Based Vaccines

What Is The Driver Of The Chikungunya Market?

The rising prevalence of mosquito-borne diseases is expected to propel the growth of the chikungunya market going forward. Mosquito-borne diseases, such as chikungunya, dengue, and zika virus, are transmitted to humans by infected aedes mosquitoes and pose significant public health challenges globally. The rising global incidence of mosquito-borne diseases is due to climate change, urbanization, deforestation, stagnant water accumulation, inadequate vector control measures, increased global travel, and insecticide resistance. Chikungunya treatment supports mosquito-borne disease patients by alleviating symptoms such as fever, joint pain, and inflammation, improving overall comfort and mobility, reducing the risk of complications, and enhancing recovery through hydration, pain management, and supportive care. For instance, in December 2024, according to the UK Health Security Agency, a UK-based government agency, Between January and June 2024, reported dengue cases among returning travelers in England, Wales, and Northern Ireland surged to 473, marking a 201% increase compared to the 157 cases recorded during the same period in 2023. Therefore, the increasing global incidence of mosquito-borne diseases is driving the growth of the chikungunya industry.

Key Players In The Global Chikungunya Market

Major companies operating in the chikungunya market are F Hoffmann‑La Roche Ltd, Merck & Co Inc, Takeda Pharmaceutical Company Limited, Evotec SE, Valneva SE, Vaxart Inc, Inovio Pharmaceuticals Inc, Bharat Biotech International Limited, Moderna Inc, Emergent BioSolutions Inc, GlaxoSmithKline plc, Sanofi Pasteur, Instituto Butantan, Indian Immunologicals Limited, Zydus Lifesciences, BioNTech SE, Novavax Inc, Bavarian Nordic A S, Auro Vaccines LLC, Najit Technologies Inc, Clayton Biotechnologies Inc, Medigen Vaccine Biologics Corp

Global Chikungunya Market Trends and Insights

Major companies operating in the chikungunya market are focusing on developing innovative vaccines to enhance immunity, prevent disease outbreaks, and address the growing global health burden of chikungunya virus infections. A live attenuated chikungunya vaccine is a vaccine that uses a weakened form of the chikungunya virus to stimulate an immune response without causing the disease, providing long-lasting protection. For instance, in November 2023, Valneva SE, a France-based biotechnology company announced IXCHIQ, a live attenuated chikungunya vaccine approved by the Food and Drug Administration (FDA), a US-based government agency. This approval was made under accelerated approval based on anti-CHIKV neutralizing antibody titers, with continued approval contingent upon verification of clinical benefit in confirmatory studies. Valneva received a Priority Review Voucher (PRV) from the FDA, which the company intends to monetize to help finance its research and development programs. Ixchiq is given as a single-dose injection into the muscle and contains a live, weakened form of the chikungunya virus, which may cause symptoms in recipients similar to those of chikungunya disease.

What Are Latest Mergers And Acquisitions In The Chikungunya Market?

In February 2023, Bavarian Nordic A/S, a Denmark-based biotechnology company acquired travel vaccines from Emergent BioSolutions Inc. for USD 380 million. With this acquisition, Bavarian Nordic A/S aims to strengthen its position in the travel vaccine by acquiring marketed travel vaccines including Vivotif for the prevention of typhoid fever, Vaxchora for cholera along with a phase 3 vaccine candidate for the prevention of chikungunya virus. Emergent BioSolutions Inc. is a US-based life sciences company that offers chikungunya vaccines.

Regional Outlook

North America was the largest region in the chikungunya market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chikungunya Market?

The chikungunya market consists of revenues earned by entities by providing services such as vaccination services, diagnostic testing services, and consultation and medical care. The market value includes the value of related goods sold by the service provider or included within the service offering. The chikungunya market also includes sales of vaccines, diagnostic kits, supportive therapies, and diagnostic equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chikungunya Market Report 2026?

The chikungunya market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chikungunya industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.